 <h1>Fosnetupitant / palonosetron Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to fosnetupitant/palonosetron: intravenous powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, fosnetupitant / palonosetron may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking fosnetupitant / palonosetron:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Agitation</li>
<li>confusion</li>
<li>cough or hoarseness</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>hearing or seeing things that are not there</li>
<li>hives, itching, skin rash</li>
<li>irritation</li>
<li>joint pain, stiffness or swelling</li>
<li>muscle twitching</li>
<li>overactive reflexes</li>
<li>poor coordination</li>
<li>redness of the skin</li>
<li>shivering</li>
<li>sweating</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>tightness in the chest</li>
<li>trembling or shaking</li>
<li>trouble breathing or swallowing</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of fosnetupitant / palonosetron may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Headache</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Constipation</li>
<li>heartburn</li>
<li>indigestion</li>
<li>stomach discomfort, upset, or pain</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to fosnetupitant / palonosetron: intravenous powder for injection</i></p><h3>Gastrointestinal</h3><p><b>Frequency not reported</b>: Constipation, dyspepsia</p>
<p></p>
<p>Palonosetron:</p>
<p><b>Common</b> (1% to 10%): Constipation, dyspepsia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Asthenia, fatigue</p>
<p></p>
<p>Palonosetron:</p>
<p><b>Common</b> (1% to 10%): Asthenia, fatigue<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Frequency not reported</b>: Headache, serotonin syndrome</p>
<p></p>
<p>Palonosetron:</p>
<p><b>Common</b> (1% to 10%): Headache<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Erythema</p>
<p></p>
<p>Palonosetron: </p>
<p><b>Common</b> (1% to 10%): Erythema<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Palonosetron:</p>
<p><b>Uncommon</b> (0.1% to 1%): Elevated AST, elevated ALT, elevated total bilirubin<sup>[Ref]</sup></p><p>Approximately 0.6% of patients given 0.5 mg of palonosetron developed AST greater than 3 times the upper limit of normal (ULN) and/or ALT greater than 3 x ULN with total bilirubin greater than ULN.  Approximately 0.2% of patients given the same dose of palonosetron developed AST greater than 10 x ULN and/or ALT greater than 10 x ULN with total bilirubin greater than ULN, and approximately 0.1% of patients developed AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than or equal to 2 x ULN.</p>
<p></p>
<p>Approximately 0.3% of patients given oral formulations of netupitant-palonosetron developed AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than ULN, and AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than or equal to 2 x ULN occurred in up to 0.1% of patients.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity reactions<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about fosnetupitant / palonosetron</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: miscellaneous antiemetics</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Fosnetupitant/palonosetron Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Nausea/Vomiting, Chemotherapy Induced</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to fosnetupitant / palonosetron: intravenous powder for injection</i></p><h3>Gastrointestinal</h3><p><b>Frequency not reported</b>: Constipation, dyspepsia</p><p></p><p>Palonosetron:</p><p><b>Common</b> (1% to 10%): Constipation, dyspepsia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Asthenia, fatigue</p><p></p><p>Palonosetron:</p><p><b>Common</b> (1% to 10%): Asthenia, fatigue<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Frequency not reported</b>: Headache, serotonin syndrome</p><p></p><p>Palonosetron:</p><p><b>Common</b> (1% to 10%): Headache<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Erythema</p><p></p><p>Palonosetron: </p><p><b>Common</b> (1% to 10%): Erythema<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Palonosetron:</p><p><b>Uncommon</b> (0.1% to 1%): Elevated AST, elevated ALT, elevated total bilirubin<sup>[Ref]</sup></p><p>Approximately 0.6% of patients given 0.5 mg of palonosetron developed AST greater than 3 times the upper limit of normal (ULN) and/or ALT greater than 3 x ULN with total bilirubin greater than ULN.  Approximately 0.2% of patients given the same dose of palonosetron developed AST greater than 10 x ULN and/or ALT greater than 10 x ULN with total bilirubin greater than ULN, and approximately 0.1% of patients developed AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than or equal to 2 x ULN.</p><p></p><p>Approximately 0.3% of patients given oral formulations of netupitant-palonosetron developed AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than ULN, and AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than or equal to 2 x ULN occurred in up to 0.1% of patients.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity reactions<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ. </p><h2>More about fosnetupitant / palonosetron</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: miscellaneous antiemetics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Fosnetupitant/palonosetron Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Nausea/Vomiting, Chemotherapy Induced</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>